RGNX
REGENXBIO Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.92
−3.04%Year over year
Reported trailing growth
- Revenue
- +12.0%
- EBITDA
- -7.1%
- EBIT
- +0.3%
- EPS
- -10.2%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -51.8%
- EBITDA
- -33.2%
- EPS
- -18.5%
Three-year CAGR
- Revenue
- +14.8%
- EBITDA
- +32.8%
- EBIT
- +30.9%
- Net income
- +14.6%
- EPS
- +18.1%
- Free cash flow
- +28.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026